Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients
Ramchandren S, Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Mantecon M, Ling L, Zhu Y, Karcher K, Sun H. Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology 2022, 99: s35-s37. DOI: 10.1212/01.wnl.0000903304.73134.e3.Peer-Reviewed Original ResearchPhase 2 studyMyasthenia gravis patientsClinical improvementGravis patientsMonoclonal antibodiesAnti-AChR autoantibodiesMuSK-positive patientsMyasthenia Gravis ActivitiesDaily living scoreSerum total IgGSerum IgG levelsMG-ADL scoreNeonatal Fc receptorGMG patientsClinical responseDose armLiving scorePathogenic autoantibodiesPositive patientsIgG levelsPathogenic antibodiesIgG autoantibodiesPharmacodynamic effectsSerum IgGTotal IgGSerum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients (S25.007)
Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Ling L, Zhu Y, Karcher K, Ramchandren S, Sun H. Serum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients (S25.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.407.Peer-Reviewed Original Research